logo
Sign in

KHTRF Stock Price, Chart, Stats & News

Knight Therapeutics Inc.
Save

Knight Therapeutics Inc. (KHTRF) does not currently pay a dividend.

733.40M
Market cap
68.43x
Current P/E
35.34x
Forward P/E

KHTRF chart

About

Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry

Knight Therapeutics Inc. operates as a specialized pharmaceutical enterprise, actively engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of a broad spectrum of pharmaceutical goods, consumer health solutions, and medical devices. Its operational footprint extends across Canada, Latin America, and other global markets. The company's extensive product offerings encompass treatments like Nerlynx, targeting extended adjuvant and metastatic breast cancer; Tafasitamab, prescribed for relapsed or refractory diffuse large B-cell lymphoma; and Pemigatinib, designed for metastatic cholangiocarcinoma.

Similar securities

Based on sector and market capitalization

Report issue